Reparixin trial status to be presented in SABCS conference

The trial focuses on Reparixin’s oral administration in combination with paclitaxel in women with metastatic breast cancer.

The completed second cohort, in which patients were not limited to toxicity, has supported the safety profile for the candidate drug.

In addition to second cohort, a third cohort with 15 patients in 3 different centers in the US is being carried out and is expected to be completed in the first quarter of 2013.

The author of the presentation Dr Anne Schott said Reparixin is a promising molecule, with a good safety profile, as the positive conclusion of the second study cohort on women with metastatic cancer has shown.

Based on the safety profile demonstrated, Dopme is also planning a clinical study in 7 US Clinical Centers to evaluate the effects of Reparixin in oral monotherapy on CSCs and on tumor microenvironment to treat women with early stage breast cancer, before surgery.

Discovered by Dompé’s research laboratories, Reparixin is an inhibitor of the CXCR1 receptor activated by chemokine interleukin 8.

Dompé Group chief executive officer Eugenio Aringhieri said,"Reparixin is one of the molecules fruit of our commitment in R&D and the results achieved so far, stimulate us to face a complex and innovative development program in the field of oncology, an area still characterized by a high therapeutical need.